WCMNY
APGB

Westchester Capital Management (New York)’s Apollo Strategic Growth Capital II APGB Stock Holding History

Westchester Capital Management (New York)’s Portfolio APGB Stock Details APGB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-1,775,426
Closed -$18.7M – 328
2023
Q3 		$18.7M Sell
1,775,426
-300,000
-14% -$3.13M 0.54% 34
2023
Q2 		$18.3M Sell
2,075,426
-1,979,465
-49% -$20.3M 0.58% 35
2023
Q1 		$41.6M Buy
4,054,891
+1,385,206
+52% +$14.1M 1.26% 12
2022
Q4 		$26.8M Buy
2,669,685
+1,909,996
+251% +$19M 0.73% 21
2022
Q3 		$7.5M Buy
759,689
+559,689
+280% +$5.51M 0.21% 74
2022
Q2 		$1.97M Hold
200,000
– – 0.05% 240
2022
Q1 		$1.96M Hold
200,000
– – 0.05% 237
2021
Q4 		$1.96M Hold
200,000
– – 0.06% 211
2021
Q3 		$1.95M Buy
+200,000
New +$1.94M 0.06% 174

Westchester Capital Management (New York)'s APGB Position: Q4 2023 in Review

Westchester Capital Management (New York) sold out of Apollo Strategic Growth Capital II (APGB) in Q4 2023, closing a stake of 1,775,426 shares — an estimated $18.7M sold.

Westchester Capital Management (New York) first reported a position in APGB in Q3 2021 and held it in 9 quarters. The position peaked at $41.6M in Q1 2023. 0 funds tracked by Wall St. Rank hold APGB as of Q4 2023.

  • Westchester Capital Management (New York) reported no remaining Apollo Strategic Growth Capital II position as of Q4 2023 after selling out during the quarter.
  • Westchester Capital Management (New York) sold 1,775,426 Apollo Strategic Growth Capital II shares in Q4 2023, an estimated $18.7M.
  • Westchester Capital Management (New York) first reported a position in Apollo Strategic Growth Capital II in Q3 2021 and held it in 9 quarters.
  • Westchester Capital Management (New York)'s Apollo Strategic Growth Capital II position peaked at $41.6M in Q1 2023.
  • 0 funds tracked by Wall St. Rank held Apollo Strategic Growth Capital II as of Q4 2023.

Based on Westchester Capital Management (New York)'s 13F filing for Q4 2023, filed 15 Feb 2024.